Avivagen Receives U.S. Re-Orders For Oximunol„¢ Supplement
(via Thenewswire.ca)
OTTAWA, ONTARIO, May 9, 2013 - Avivagen Inc. (TSXV:VIV), a wellness company committed to developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces its receipt of U.S. re-orders for its Oximunol(TM) Chewable Tablets for Dogs.
These re-orders follow from the autumn, 2012 launch of Oximunol(TM) canine in the United States by Avivagen's U.S. distribution partner. The re-order is for both product sizes, the tablet containing 20 mg of OxC-beta for larger dogs and that containing 5 mg for smaller dogs. Financial details relating to the order will be disclosed in Avivagen's statements for the relevant fiscal quarter.